Heart Failure
Conditions
Keywords
Heart failure, Exercise, Biomarkers, Sympathetic Nervous System, MicroRNA
Brief summary
BACKGROUND: The physiopathology of the heart failure involves compensatory mechanisms as exacerbated neurohormonal activity, endothelial dysfunction and consequently the muscle disability and exercise intolerance. The interval exercise training has been proposed as one efficient method to heart failure patients. It seems that the main mechanism involved in the benefit of the interval exercise training is shear stress. AIM: To study the interval exercise training versus the continuous exercise training in the sympathetic activity and in the peripheral muscle perfusion in heart failure patients. Moreover, we will evaluate the muscle apoptosis, microRNA in plasma and muscle biopsy, biomarkers levels of inflammation, quality of life and exercise capacity. METODOLOGY: Will be selected 40 patients (male and female) with age between 30 and 60 years, left ventricular ejection fraction less than 40% and functional class I, II and III. These patients will be randomized into three groups: Interval (AIT), continuous (MCT) and control (CG). All patients will be evaluated with microneurography, peripheral muscle perfusion, muscle biopsy, blood samples, accelerometer, cardiopulmonary exercise test and quality of life before and after end of the period of 03 (three) months.
Interventions
Patients will be submitted to three months aerobic exercise training, three times per week. Each session will have two levels of intensity: one minute at respiratory compensation point heart rate intercalating with two minutes at anaerobic threshold heart rate during thirty minutes.
Patients will be submitted to three months aerobic exercise training, three times per week. Each session will have only one level of intensity during stimulus phase of exercise, lasting thirty minutes: heart rate (HR) target is defined as 1/3x(HR at respiratory compensation point) + 2/3x(HR anaerobic threshold)
Sponsors
Study design
Eligibility
Inclusion criteria
* stable chronic heart failure without changing in treatment for at least 6 weeks * ejection fraction less then 40%, as measured by transthoracic echocardiography * optimal clinical treatment for chronic heart failure according to current guidelines.
Exclusion criteria
* asthma or chronic obstructive pulmonary disease using inhaled corticosteroids * functional class IV (New York Heart Association - NYHA) * atrial fibrillation * complex ventricular arrhythmia * pacemaker or implantable cardioversor/defibrillators * chronic renal insufficiency, defined as serum creatinine above 2,5 mg/dL * intermittent claudication * morbid obesity * cirrhosis * alcoholism * using illicit drugs * performing regular physical activity * participating in another study * invasive procedure planned * persistent nonadherence to therapeutic regimen * peak respiratory exchange ratio (RER) lower than 1.00
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Muscular sympathetic nervous activity | 12 weeks | Muscular sympathetic nervous activity was measured by in peroneal nerve microneurography. |
| Peripheral muscular perfusion | 12 weeks | Peripheral muscular perfusion was measured by near-infrared spectroscopy (NIRS) above vastus lateral muscle during exercise. |
| Biomarkers | 12 weeks | Serum levels of biomarkers of inflammation (interleukin-6, tumor necrosis factor alpha and adiponectin) and fibrosis (galectin-3). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Daily life physical activity | 12 weeks | Daily life physical activity determined by Baecke physical activity questionnaire and by a triaxial digital accelerometer during 24 hs. |
| MicroRNA | 12 weeks | Blood levels of selected microRNAs |
Countries
Brazil